Show simple item record

dc.contributor.authorThatcher, Nick
dc.contributor.authorLorigan, Paul C
dc.contributor.authorBurt, Paul A
dc.contributor.authorStout, Ronald
dc.date.accessioned2010-04-22T09:37:56Z
dc.date.available2010-04-22T09:37:56Z
dc.date.issued1994-06
dc.identifier.citationIntensive combined-modality therapy in small cell lung cancer. 1994, 21 (3 Suppl 6):9-22 Semin. Oncol.en
dc.identifier.issn0093-7754
dc.identifier.pmid8052879
dc.identifier.urihttp://hdl.handle.net/10541/97135
dc.description.abstractCombination ifosfamide/carboplatin/etoposide (ICE) chemotherapy and ICE plus mid-cycle vincristine (VICE) are reviewed. Thoracic radiotherapy and prophylactic cranial irradiation given as single fractions in the majority of patients have been intercalated with VICE in the later studies. The patient populations have not been intensively staged with computed tomography, etc, but do have reasonable Karnofsky performance status ratings and biochemical screens. A policy of no dose reduction over six courses of VICE chemotherapy has been followed in three consecutive studies of 166 patients. The minimum length of follow-up is 26 months and the 2-year survival rate is > or = 30%. Hematopoietic growth factor support in an attempt to overcome the considerable myelosuppression with VICE therapy is currently being evaluated.
dc.language.isoenen
dc.subjectLung Canceren
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshCarboplatin
dc.subject.meshCarcinoma, Small Cell
dc.subject.meshChemotherapy, Adjuvant
dc.subject.meshCisplatin
dc.subject.meshClinical Trials as Topic
dc.subject.meshEtoposide
dc.subject.meshHumans
dc.subject.meshIfosfamide
dc.subject.meshLung Neoplasms
dc.subject.meshVincristine
dc.titleIntensive combined-modality therapy in small cell lung cancer.en
dc.typeArticleen
dc.contributor.departmentCRC Department of Medical Oncology, Christie Hospital, Manchester, UK.en
dc.identifier.journalSeminars in Oncologyen
html.description.abstractCombination ifosfamide/carboplatin/etoposide (ICE) chemotherapy and ICE plus mid-cycle vincristine (VICE) are reviewed. Thoracic radiotherapy and prophylactic cranial irradiation given as single fractions in the majority of patients have been intercalated with VICE in the later studies. The patient populations have not been intensively staged with computed tomography, etc, but do have reasonable Karnofsky performance status ratings and biochemical screens. A policy of no dose reduction over six courses of VICE chemotherapy has been followed in three consecutive studies of 166 patients. The minimum length of follow-up is 26 months and the 2-year survival rate is > or = 30%. Hematopoietic growth factor support in an attempt to overcome the considerable myelosuppression with VICE therapy is currently being evaluated.


This item appears in the following Collection(s)

Show simple item record